CD274 and hepatocellular carcinoma: In spite of the fact that immune checkpoint inhibitors (ICIs) towards PD-1 or PD-L1 that have emerged in recent years have shown partial efficacy in HCC patients, the overall clinical effectiveness rate is low, accounting for only around 20% of patients 3.